<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451606</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00047688</org_study_id>
    <nct_id>NCT01451606</nct_id>
  </id_info>
  <brief_title>Duloxetine for the Treatment of Chronic Pelvic Pain</brief_title>
  <official_title>Evaluating Duloxetine's Analgesic Effectiveness in Chronic Pelvic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is examining the effectiveness of duloxetine as a treatment for chronic pelvic
      pain in women. Duloxetine is FDA approved for the treatment of other pain conditions,
      including fibromyalgia and diabetic neuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic pelvic pain in women can be caused by various pathologies, such as endometriosis,
      fibroids, and adhesions. Surgical treatment of the pathology often relieves the pain, but a
      significant number of women continue to have pain, even after visibly successful surgery. One
      model explored in this study is that in some cases of chronic pelvic pain, the central
      nervous system has changed in its processing of pain-related signals, requiring a therapy
      directed to the Central Nervous System (CNS) to effectively treat the pain. This model has
      been supported in studies of other chronic pain conditions, such as fibromyalgia and
      migraine. This study will seek to determine whether the analgesic effectiveness of duloxetine
      is related to the pain state of the individual.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Adequate recruitment was not achieved in the time frame allowed.
  </why_stopped>
  <start_date type="Actual">July 11, 2011</start_date>
  <completion_date type="Actual">November 4, 2015</completion_date>
  <primary_completion_date type="Actual">November 4, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One group receiving active drug treatment and second group receiving an indistinguishable placebo pill.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Study drug allocation was determined by University pharmacy, using a random allocation algorithm unknown by researchers or patients.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Rating of Spontaneous Pelvic Pain (0 -10 Scale).</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The primary clinical efficacy measure is the change in spontaneous (non-evoked) pelvic pain from the baseline period to the end of treatment. This was assessed by using the 0-10 numerical pain ratings to derive the primary outcome variable of clinical pain intensity difference due to treatment. Larger values (greater changes in ratings) are better outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Endometriosis Health Profile - 30 Subscale for Functional Limitations Due to Pain</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>This is a questionnaire assessment of functional limitations due to clinical pain. The range of scores for this subscale is 0-44. The measure is the change in score from baseline to end of treatment period. A greater number (change in score) is a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Pelvis Pain Chronic</condition>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A pill that looks like the active drug, but does not contain any active ingredients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The drug, Duloxetine, is marketed under the trade name Cymbalta. It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>To serve as placebo for duloxetine. Administration schedule same as for active drug.</description>
    <arm_group_label>Placebo pill</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premenopausal adult women, aged 18-50

          -  Have chronic pelvic pain, as defined by the American College of Obstetrics and
             Gynecology

          -  Able to read and speak English

        Exclusion Criteria:

          -  Chronic Pelvic Pain (CPP) only presenting in low back or vulva, or only present during
             menstruation or vaginal intercourse

          -  Self-report or documentation that all CPP sites were attributed by a prior physician
             to Irritable Bowel Syndromd (IBS), Interstitial cystitis (IC)/painful bladder syndrome
             (PBS), urinary tract infection, urinary stones, inflammatory bowel disease (ulcerative
             colitis or Crohn's disease), cancer or shingles.

          -  Currently pregnant or lactating

          -  A primary psychiatric diagnosis of major depression or history of suicide attempt as
             assessed by medical history. Also, those who would be considered to have Major
             Depressive Disorder (MDD) on the basis of the Diagnostic and Statistical Manual IV
             (DSM-IV) criteria will excluded, as well as those selecting &quot;3&quot; or &quot;4&quot; on item #9 of
             the Beck Depression Inventory (BDI; suicidal ideation).

          -  A history of bipolar disorder

          -  A history of seizure disorders

          -  Orthostatic Hypertension

          -  Exclusions based on the effects of duloxetine:

               1. Known hypersensitivity to duloxetine or the inactive ingredients in Cymbalta;

               2. Treatment with an monoamine oxidase inhibitor (MAOI) within 14 days of
                  randomization, or potential need to use an MAOI during the study or within 5 days
                  of discontinuation of the drug;

               3. Treatment with cytochrome P450 enzyme inhibitors;

               4. Uncontrolled narrow-angle glaucoma;

               5. Concurrent use of thioridazine

               6. Renal Impairment (serum creatinine of 1.5 or greater)

               7. History of jaundice or hepatomegaly

               8. Hepatic Insufficiency (elevated aspartate transaminase (AST), alanine
                  transaminase (ALT), bilirubin, or Alkaline Phosphatase), tested at the screening
                  period, after the first week of study medication, and again at the midpoint of
                  the study.

          -  Participants who are taking Selective serotonin reuptake inhibitors (SSRIs), Selective
             serotonin and norepinephrine reuptake inhibitors (SSNRIs), monoamine oxidase
             inhibitors (MAOIs), or tricyclics within 14 days of randomization will be excluded.

          -  Participants who currently meet DSM-IV diagnostic criteria for Alcohol Abuse or
             Dependence

          -  Weight exceeding 285 pounds

          -  Hyponatremia, as determined by blood test results
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Greenspan, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Of Maryland Dental School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <results_first_submitted>December 1, 2017</results_first_submitted>
  <results_first_submitted_qc>December 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2018</results_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Joel Greenspan</investigator_full_name>
    <investigator_title>Professor and Chair</investigator_title>
  </responsible_party>
  <keyword>Chronic Pelvic Pain (CPP)</keyword>
  <keyword>Pelvic Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: July 2011 - Dec. 2015. Recruitment from medical clinic and through public advertisements.</recruitment_details>
      <pre_assignment_details>In person visit to complete eligibility screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Pill</title>
          <description>A pill that looks like the active drug, but does not contain any active ingredients.
Placebo: To serve as placebo for duloxetine. Administration schedule same as for active drug.</description>
        </group>
        <group group_id="P2">
          <title>Duloxetine</title>
          <description>The drug, Duloxetine, is marketed under the trade name Cymbalta. It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).
Duloxetine: 30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Pill</title>
          <description>A pill that looks like the active drug, but does not contain any active ingredients.
Placebo: To serve as placebo for duloxetine. Administration schedule same as for active drug.</description>
        </group>
        <group group_id="B2">
          <title>Duloxetine</title>
          <description>The drug, Duloxetine, is marketed under the trade name Cymbalta. It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).
Duloxetine: 30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Rating of Spontaneous Pelvic Pain (0 -10 Scale).</title>
        <description>The primary clinical efficacy measure is the change in spontaneous (non-evoked) pelvic pain from the baseline period to the end of treatment. This was assessed by using the 0-10 numerical pain ratings to derive the primary outcome variable of clinical pain intensity difference due to treatment. Larger values (greater changes in ratings) are better outcomes.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Pill</title>
            <description>A pill that looks like the active drug, but does not contain any active ingredients.
Placebo: To serve as placebo for duloxetine. Administration schedule same as for active drug.</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine</title>
            <description>The drug, Duloxetine, is marketed under the trade name Cymbalta. It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).
Duloxetine: 30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rating of Spontaneous Pelvic Pain (0 -10 Scale).</title>
          <description>The primary clinical efficacy measure is the change in spontaneous (non-evoked) pelvic pain from the baseline period to the end of treatment. This was assessed by using the 0-10 numerical pain ratings to derive the primary outcome variable of clinical pain intensity difference due to treatment. Larger values (greater changes in ratings) are better outcomes.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.52</p_value>
            <p_value_desc>Note that sample size was well below our target, making this test very low power.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Endometriosis Health Profile - 30 Subscale for Functional Limitations Due to Pain</title>
        <description>This is a questionnaire assessment of functional limitations due to clinical pain. The range of scores for this subscale is 0-44. The measure is the change in score from baseline to end of treatment period. A greater number (change in score) is a better outcome.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Pill</title>
            <description>A pill that looks like the active drug, but does not contain any active ingredients.
Placebo: To serve as placebo for duloxetine. Administration schedule same as for active drug.</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine</title>
            <description>The drug, Duloxetine, is marketed under the trade name Cymbalta. It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).
Duloxetine: 30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Endometriosis Health Profile - 30 Subscale for Functional Limitations Due to Pain</title>
          <description>This is a questionnaire assessment of functional limitations due to clinical pain. The range of scores for this subscale is 0-44. The measure is the change in score from baseline to end of treatment period. A greater number (change in score) is a better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.58" spread="26.73"/>
                    <measurement group_id="O2" value="12.92" spread="22.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were recorded for the duration of a participants time in the study, including 2 weeks after end of treatment. For the entire study, AEs were noted from July 2011 - Dec. 2015.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Pill</title>
          <description>A pill that looks like the active drug, but does not contain any active ingredients.
Placebo: To serve as placebo for duloxetine. Administration schedule same as for active drug.</description>
        </group>
        <group group_id="E2">
          <title>Duloxetine</title>
          <description>The drug, Duloxetine, is marketed under the trade name Cymbalta. It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).
Duloxetine: 30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="12" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joel Greenspan</name_or_title>
      <organization>University of Maryland, Baltimore</organization>
      <phone>4107067090</phone>
      <email>jgreenspan@umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

